Estimation of Secondary Household Attack Rates for Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco.

SARS-CoV-2 household transmission secondary attack rates spike mutation variant

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
07 01 2022
Historique:
received: 02 03 2021
accepted: 29 03 2021
pubmed: 1 4 2021
medline: 15 1 2022
entrez: 31 3 2021
Statut: ppublish

Résumé

Sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral genome from patient samples is an important epidemiological tool for monitoring and responding to the pandemic, including the emergence of new mutations in specific communities. SARS-CoV-2 genomic sequences were generated from positive samples collected, along with epidemiological metadata, at a walk-up, rapid testing site in the Mission District of San Francisco, California during 22 November to 1 December, 2020, and 10-29 January 2021. Secondary household attack rates and mean sample viral load were estimated and compared across observed variants. A total of 12 124 tests were performed yielding 1099 positives. From these, 928 high-quality genomes were generated. Certain viral lineages bearing spike mutations, defined in part by L452R, S13I, and W152C, comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household contacts exposed to the "California" or "West Coast" variants (B.1.427 and B.1.429) were at higher risk of infection compared to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, risk ratio [RR] = 1.28; 95% confidence interval [CI]: 1.00-1.64). The reproductive number was estimated to be modestly higher than other lineages spreading in California during the second half of 2020. Viral loads were similar among persons infected with West Coast versus non-West Coast strains, as was the proportion of individuals with symptoms (60.9% vs 64.3%). The increase in prevalence, relative household attack rates, and reproductive number are consistent with a modest transmissibility increase of the West Coast variants. Summary: We observed a growing prevalence and modestly elevated attack rate for "West Coast" severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in a community testing setting in San Francisco during January 2021, suggesting its modestly higher transmissibility.

Sections du résumé

BACKGROUND
Sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral genome from patient samples is an important epidemiological tool for monitoring and responding to the pandemic, including the emergence of new mutations in specific communities.
METHODS
SARS-CoV-2 genomic sequences were generated from positive samples collected, along with epidemiological metadata, at a walk-up, rapid testing site in the Mission District of San Francisco, California during 22 November to 1 December, 2020, and 10-29 January 2021. Secondary household attack rates and mean sample viral load were estimated and compared across observed variants.
RESULTS
A total of 12 124 tests were performed yielding 1099 positives. From these, 928 high-quality genomes were generated. Certain viral lineages bearing spike mutations, defined in part by L452R, S13I, and W152C, comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household contacts exposed to the "California" or "West Coast" variants (B.1.427 and B.1.429) were at higher risk of infection compared to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, risk ratio [RR] = 1.28; 95% confidence interval [CI]: 1.00-1.64). The reproductive number was estimated to be modestly higher than other lineages spreading in California during the second half of 2020. Viral loads were similar among persons infected with West Coast versus non-West Coast strains, as was the proportion of individuals with symptoms (60.9% vs 64.3%).
CONCLUSIONS
The increase in prevalence, relative household attack rates, and reproductive number are consistent with a modest transmissibility increase of the West Coast variants. Summary: We observed a growing prevalence and modestly elevated attack rate for "West Coast" severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in a community testing setting in San Francisco during January 2021, suggesting its modestly higher transmissibility.

Identifiants

pubmed: 33788923
pii: 6206738
doi: 10.1093/cid/ciab283
pmc: PMC8083548
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-39

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM007810
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060537
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060530
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069496
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI150007
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Elife. 2020 Oct 28;9:
pubmed: 33112236
Sci Rep. 2020 Oct 9;10(1):16944
pubmed: 33037310
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
J Infect Dis. 2021 Apr 8;223(7):1139-1144
pubmed: 33394052
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Gigascience. 2020 Oct 15;9(10):
pubmed: 33057676
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Infect Genet Evol. 2021 Sep;93:104941
pubmed: 34044192
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
PLoS Biol. 2020 Aug 21;18(8):e3000869
pubmed: 32822393
Cell. 2021 Mar 4;184(5):1127-1132
pubmed: 33581746
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Open Forum Infect Dis. 2021 Jan 20;8(2):ofab023
pubmed: 33623805
Clin Infect Dis. 2021 Nov 2;73(9):e3098-e3101
pubmed: 33367619
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
PLoS One. 2020 Oct 9;15(10):e0239400
pubmed: 33035216
J Virol. 2021 Mar 1;:
pubmed: 33649194
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S127-S135
pubmed: 32821935
Cell. 2020 May 28;181(5):990-996.e5
pubmed: 32386545
iScience. 2020 Jun 26;23(6):101212
pubmed: 32512386

Auteurs

James Peng (J)

Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Jamin Liu (J)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.
University of California, Berkeley-University of California, San Francisco Graduate Program in Bioengineering, Berkeley, California, USA.

Sabrina A Mann (SA)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.
Chan Zuckerberg Biohub, San Francisco, California, USA.

Anthea M Mitchell (AM)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.
Chan Zuckerberg Biohub, San Francisco, California, USA.

Matthew T Laurie (MT)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.

Sara Sunshine (S)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.

Genay Pilarowski (G)

Department of Pathology, Stanford University, Stanford, California, USA.

Patrick Ayscue (P)

Chan Zuckerberg Biohub, San Francisco, California, USA.

Amy Kistler (A)

Chan Zuckerberg Biohub, San Francisco, California, USA.

Manu Vanaerschot (M)

Chan Zuckerberg Biohub, San Francisco, California, USA.

Lucy M Li (LM)

Chan Zuckerberg Biohub, San Francisco, California, USA.

Aaron McGeever (A)

Chan Zuckerberg Biohub, San Francisco, California, USA.

Eric D Chow (ED)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.

Carina Marquez (C)

Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Robert Nakamura (R)

California Department of Public Health, Richmond, California, USA.

Luis Rubio (L)

Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Gabriel Chamie (G)

Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Diane Jones (D)

Unidos en Salud, San Francisco, California, USA.

Jon Jacobo (J)

Unidos en Salud, San Francisco, California, USA.

Susana Rojas (S)

Unidos en Salud, San Francisco, California, USA.

Susy Rojas (S)

Unidos en Salud, San Francisco, California, USA.

Valerie Tulier-Laiwa (V)

Unidos en Salud, San Francisco, California, USA.

Douglas Black (D)

Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Jackie Martinez (J)

Unidos en Salud, San Francisco, California, USA.

Jamie Naso (J)

Unidos en Salud, San Francisco, California, USA.

Joshua Schwab (J)

Division of Biostatistics, University of California, Berkeley, Berkeley, California, USA.

Maya Petersen (M)

Division of Biostatistics, University of California, Berkeley, Berkeley, California, USA.

Diane Havlir (D)

Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Joseph DeRisi (J)

Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.
Chan Zuckerberg Biohub, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH